SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-001858
Filing Date
2023-01-06
Accepted
2023-01-06 16:15:20
Documents
12
Period of Report
2022-12-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm232381d1_8k.htm   iXBRL 8-K 32504
  Complete submission text file 0001104659-23-001858.txt   207312

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acrs-20221231.xsd EX-101.SCH 3036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrs-20221231_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrs-20221231_pre.xml EX-101.PRE 22597
6 EXTRACTED XBRL INSTANCE DOCUMENT tm232381d1_8k_htm.xml XML 3591
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 23515241
SIC: 2834 Pharmaceutical Preparations